Securities code: 688289 securities abbreviation: Sansure Biotech Inc(688289) Announcement No.: 2022-010 Sansure Biotech Inc(688289)
Announcement of 2021 annual performance express
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
The main financial data of 2021 contained in this announcement are preliminary accounting data, which have not been audited by an accounting firm. The specific data shall be subject to the 2021 annual report of Sansure Biotech Inc(688289) (hereinafter referred to as “the company”), which draws the attention of investors to investment risks.
1、 Main financial data and indicators in 2021
Unit: 10000 yuan
Increase / decrease range of the project in the same period of last year in the reporting period (%)
Total operating income 450596.07 476296.39 -5.40
Operating profit 262024.89 308603.12 -15.09
Total profit 261526.71 307016.06 -14.82
Owned by the parent company 222215.06 261659.70 -15.07
The net profit of the company belongs to the parent company
Deduction of non recurring 212970.58 259267.57 -17.86
Net profit from profit or loss
Basic earnings per share (yuan) 5.56 7.01 -20.68
The weighted average net assets closed at 38.74% and 107.29%, with a decrease of 68.55 percentage points
Increase / decrease range at the end of the reporting period (%)
Total assets 704717.17 545437.41 29.20
456379.4742.4710 attributable to the parent company
Owner’s rights and interests
Share capital 40000.00 40000.00 0.00
Owned by the parent company
Their net assets per share were 15.87, 11.86 and 33.81
(yuan) Note: 1 The beginning amount of this report is the same as the end amount of the previous year legally disclosed.
2. The above financial data and indicators are filled in with the data in the consolidated statements, but have not been audited. The final results are subject to the company’s 2021 annual report.
2、 Description of operating performance and financial status
(I) operating conditions, financial conditions and main factors affecting operating performance during the reporting period
1. Operation: in 2021, the company achieved a total operating income of 450.59607 million yuan, a slight decrease of 5.40% over the same period of last year; The net profit attributable to the owners of the parent company was 2222150600 yuan, a decrease of 15.07% over the same period of last year; The net profit attributable to the owner of the parent company after deducting non recurring profits and losses was 2129.7058 million yuan, a decrease of 17.86% over the same period of the previous year.
2. Financial status: the total assets of the company at the end of 2021 were 7047.1717 million yuan, an increase of 29.20% over the same period of last year; The owner’s equity attributable to the parent company was 6349.1089 million yuan, an increase of 33.79% over the same period last year. 3. Main factors affecting operating performance:
(1) the company’s operating income and net profit declined slightly during the reporting period, due to the fact that China’s New Coronavirus test reagent collection and the prices of COVID-19 related products in the global market were generally down. According to the needs of epidemic prevention and control, the company immediately adjusted the product structure and supply strategy related to covid-19, and gradually launched solutions adapted to different scenarios and needs to meet the needs of the global market. At present, the “Shengxiang scheme” is still the leading anti epidemic scheme in many countries around the world. During the reporting period, the delivery volume of covid-19 nucleic acid detection reagent of the company reached 219897700 people, an increase of 134.66% over the same period of the previous year. In the whole year, 10696 instruments were delivered, an increase of 74.71% over the same period of the previous year, which provided a strong support for further driving the quantity of reagents and accelerating the market share of the whole line of products.
(2) The company continued to increase R & D investment. In 2021, the company’s R & D expenditure reached 185 million yuan, a significant increase of 124% over the same period last year. The number of R & D personnel further increased, and gradually built an interdisciplinary composite R & D team, aiming at covid-19 whole scene scheme, accurate respiratory tract detection, blood safety, early screening and diagnosis of tumors and accompanying Continuous development and layout in the fields of second-generation sequencing and automatic instruments and equipment. At the same time, the company further strengthened its investment in international product development and registration and access, and 132 new products were registered and admitted outside China during the reporting period. The above investment increased the company’s operating costs, resulting in a slight decline in profits compared with the same period last year.
(II) description of the main reasons for the increase or decrease of more than 30% of the relevant items in the above table
1. The weighted average return on net assets of the company in 2021 decreased by 68.55 percentage points year-on-year, mainly due to the increase of share capital and capital reserve due to the initial listing of the company on the science and Innovation Board at the end of August 2020 and the significant increase of net assets due to the significant increase of profits in 2020-2021.
2. The owner’s equity attributable to the parent company and net assets per share attributable to the owner of the parent company in 2021 increased by 33.79% and 33.81% respectively compared with the beginning of the period, mainly due to the increase of corresponding undistributed profits due to the realization of net profits.
3、 Risk tips
The company has no major uncertain factors affecting the accuracy of this performance express.
The main financial data of 2021 contained in this announcement are preliminary accounting data, which have not been audited by an accounting firm. The specific data are subject to the company’s 2021 annual report, and investors are reminded of investment risks.
It is hereby announced.
Sansure Biotech Inc(688289) board of directors February 25, 2022
